Celebrate 10 years of laboratory automation, scientific education and innovation.
January 25 – 27, 2021
Live and on demand from anywhere!
Join us from home, the lab, your office or your preferred knowledge-consuming and networking spot!
SLAS2021 Digital promises to bring you quality life sciences programming and the latest product
and technology innovations you’ve come to expect – with a digital twist.
This year’s program will feature more than 80 scientific talks, 45 vendor presentations and two inspiring keynotes.
Take in content live or on demand as your schedule allows.
There will still be plenty of opportunities for you to showcase your product, service and company through impactful and attention-getting sponsor and exhibitor opportunities. We’ll be announcing New Product Awards too!
A complete Digital Sponsorship and Exhibitor Prospectus will be available in late-September.
The SLAS2021 Call for Abstracts is now open. Ignite your research by presenting a live talk or poster from the comfort of your own home. You can even wear pajama pants — who will know?!
While registration isn’t available until October, full details on this year’s pricing is.
The best part? SLAS Premier Members attend for FREE!
SLAS is excited to be going digital together. We look forward to welcoming an extended global life sciences community to this online event to Ignite Science!
Registration will open in early October.
SLAS2021 Digital access is included with SLAS premier membership. What does this mean? If your dues are paid through the 2021 calendar year, or if you’re a student, this event is FREE for you to attend.
|SLAS Member (Paid through Dec. 31, 2021)||$0.00 (FREE)|
|SLAS Non-Member||$249.00 (with option to join)|
|Students (undergraduate, graduate, post-doc)||$0.00 (FREE)|
Members include Premier, Early-Career Professional, Retired and our new Lab Level membership (you’ll be hearing more about that very soon!)
We’ll keep you informed of the details regarding SLAS2021 Digital over the coming months, and we can tell you now that it will include:
While the format for the 10th Annual SLAS International Conference and Exhibition is different for 2021, the program will include the same high-quality scientific discovery, technology and innovation research attendees have come to expect over the last decade.
SLAS2021 Digital will feature more than 80 scientific talks from 10 educational tracks and 45 vendor tutorials to ignite virtual discussions and brainstorming. SLAS2021 Digital will also feature keynote speakers Deborah Sliptez, Ph.D., (Merck) and Atul Butte, M.D., Ph.D., (University of California Health System), both of whom will deliver impactful and relevant presentations on topics sure to get you excited about the future of drug discovery and automation technology.
Log in live or take in content on-demand as your schedule allows.
Podium presentations at SLAS2021 are organized into ten educational tracks. Track and session titles and descriptions and names of track chairs and session chairs follow below.
The Scientific Program Committee selects speakers based on the innovation, relevance and applicability of research. If your proposed topic does not squarely fit into the focus of one of these tracks, please submit it for committee consideration regardless. The committee members use their judgment and experience to select presentations that best address the interests and priorities of today’s life sciences discovery and technology community.
Podium abstracts will be assessed in September and the podium program will be finalized and published by late-October.
The qualitative and quantitative characterization of endogenous and exogenous analytes in biological systems are the basis of drug discovery and development. This track will highlight important developments in bioanalytical technologies, including advances in label-free technologies, applications of target and mechanism deconvolution techniques and ‘omics approaches to biomarker analysis. Planned sessions include:
Label-Free Bioanalytical Techniques
Session Chair: Frank Buettner, Ph.D., Boehringer Ingelheim
Target Engagement and Pathways
Session Chair: Kilian Huber, Ph.D., University of Oxford
Target and Mechanism Deconvolution After Phenotypic Screens
Session Chair: Paul Tesar, Ph.D., Case Western Reserve University
This track will focus on recent innovations across the assay development and screening field, including the adoption of novel technologies and intelligent informatics approaches, to enable the implementation of effective screening campaigns and hit triage strategies to identify, validate and characterize potential leads. Attendees will hear about the development of robust, physiologically relevant biochemical, biophysical and cellular assays that are crucial for identifying active ligands that engage their targets directly. There will be an emphasis on recent case studies where cutting-edge assay approaches to improve the success rates of screening have been coupled with next-generation therapeutic modalities and novel mechanisms of action to broaden the scope of target classes that can be drugged. Planned sessions include:
Advanced Imaging and High-Content Assays
Session Chair: Regis Doyonnas, Ph.D., Pfizer
Applications of CRISPR Technology in Drug Discovery
Session Chair: Davide Gianni, Ph.D., AstraZeneca
Biochemical & Biophysical Assays
Session Chair: Larry Szewczuk, Ph.D., Janssen Pharmaceuticals
Session Chair: Patrick McEnaney, Ph.D., Haystack Sciences
In vitro Immunological Assays
Session Chair: Amy Quinn, Ph.D., GlaxoSmithKline
Session Chair: Christopher Parker, Ph.D., Scripps Research
This track focuses on the innovative use of biological or chemistry applications, tools, technologies, and techniques as they pertain to automated high throughput screening, the advancement of laboratory processes or improvement of the quality and impact of experimental laboratory data. Emphasis is placed on advancements in chemically and biologically relevant technologies using engineering, analytical, informatics, and application to cutting edge automation-assisted research. Planned sessions include:
Screening & Profiling at Higher-Throughput Using Physiologically Relevant Cell Models
Session Chair: Sylvia Boj, Ph.D., Hubrecht Organoid Technology
Technologies to Bridge the Gap Between High-Content and High-Throughput
Session Chair: James Pilling, M.S., AstraZeneca
Automating Screening Processes
Session Chair: Steven van Helden, Ph.D., Pivot Park Screening Centre
Automating Chemistry in the Age of AI
Session Chair: Lee Cronin, Ph.D., University of Glasgow
Microtiter Plates and Beyond: High-Throughput Miniaturization While Maintaining Physiological Relevance
Session Chair: Lorena Kallal, Ph.D., GlaxoSmithKline
In-house and Open Source Automation: Products, devices and software used to support laboratory automation
Session Chair: Pierre Baillargeon, M.S., Scripps Research
Attendees will learn from industry and academic leaders about new cellular technologies and their application in the understanding of normal physiology and disease, and in the generation of disease-relevant models for drug discovery and pre-clinical development. The track will cover models used for illuminating functional genomics and for pharmacology, ADME or toxicity outcomes. The technologies covered will include the generation and use of patient-derived models, iPSC models, complex co-cultures, organoids, organ-on-chips and microphysiologic models. The track will also include cellular therapeutics and cell technologies to support biologics and gene therapy approaches. Of particular interest will be the therapeutic areas of oncology, infectious diseases, immunology and rare diseases. Planned sessions include:
Novel and Innovative Applications of Cellular Technologies
Session Chair: Chris Hughes, Ph.D., Aracari Biosciences
Application of Disease-Relevant Cellular Models in Drug Discovery and Pre-Clinical Development
Session Chair: Marie-Claire Peakman, Ph.D., Pfizer
Development and Evaluation of Cellular Therapeutics
Session Chair: Sandra Santulli-Marotto, Ph.D., Bristol Myers Squibb
The world is rapidly transforming. Data are ambient and exist in volumes far exceeding the quantities imagined by the pioneers of our fields. As data volume and complexity continue to grow exponentially, so does the demand for tools that can rise to the occasion. Gone are the days of my data and your data. Analyzing single or even multiple sets of similar data will not yield the breakthroughs of the past but alongside the challenges are new opportunities for technology to empower discovery. This session will focus on the rapidly evolving role of digital technology and scientific information management as well as the hardware and software of the modern digital research lab. Emphasis will be placed on transforming data feeds from instruments into scientific understanding, particularly with the use of artificial intelligence and with additional consideration for distributed laboratories and the use of the cloud in the data ecosystem as we live through a global pandemic. Planned sessions include:
Lab of the Future
Session Chair: John Williams, Ph.D., Neurocrine
Building a Data Ecosystem
Session Chair: Marti Head, Ph.D., Oakridge National Lab
The Age of AI in the Lab
Session Chair: Joe Jacobson, Ph.D., MIT/DeepCure
Creating the next generation of small molecule drugs calls for novel drug target strategies. This track will provide assay and screening scientists with cutting edge information on technologies and methodologies that enable them to advance chemical matter for clinically relevant pharmacologies. Planned sessions include:
Drugging the Undruggable
Session Chair: Allison Olszewski, Ph.D., Civetta Therapeutics
Advances in Protein Homeostasis
Session Chair: Eunice Park, Ph.D., C4 Therapeutics
Targeting RNA Regulation
Session Chair: Tim Wigle, Ph.D., Ribon Therapeutics
Freeman Dyson famously said "when we make a new tool, we see a new cosmos". Micro and nano-scale tools have accelerated the pace of scientific discovery, particularly in next-generation sequencing, single cell analysis, analytical chemistry, high throughput screening and point-of-care diagnostics. These tools leverage unique physics at small length scales, the ability to interact and interrogate biological systems at similar length scales and the ability to massively parallelize assays. Attendees will be given a broad overview of such emerging tools and their applications from both industry and academic leaders. This year's track will highlight advances in single-cell analysis technologies, infectious disease theragnostics, and personalized medicine. Planned sessions include:
Microfluidic-Based Profiling of Eukaryotic and Microbial Cells at Single-Cell Resolution
Session Chair: Hee-Sun Han, Ph.D., University of Illinois
Disposable Near-Patient Testings for Infectious Disease
Session Chair: Nicolas Durand, Ph.D., Abionic
The emerging role of micro/nano innovations for personalized medicine
Session Chair: Soojung Hur, Ph.D., Johns Hopkins University
Planned sessions include:
Therapeutic Antibody Fragments
Session Chair: Andrew Bradbury, Ph.D., Specifica
Alternate Scaffolds with Clinical Potential
Session Chair: Yasmina Abdiche, Ph.D., Immunoprecise
Silencing Diseases at the Genetic Level Using siRNA
Session Chair: Karol Watson, M.D., Ph.D., UCLA Program in Preventive Cardiology
'Omics technologies have become an inevitable part of drug research. While much attention has been put on (chemical)-proteomics have other 'omics-technologies yet received less awareness. In this track we will put the spotlight on metabolomics, transcriptomics and glycomics as upcoming techniques for drug research and biologics characterization. Planned sessions include:
Metabolomics in Drug Research
Session Chair: Baljit Uhbi, Ph.D., Sciex
Session Chair: Valeria Orlova, Ph.D., Leiden University Medical Center
Sweetening the Pot: Recent Advances in the Characterization of Biotherapeutic Glycoproteins
Session Chair: Guinevere Lageveen-Kammeijer, Leiden University Medical Center
The Precision Medicine for Drug Discovery track focuses on approaches that aim to resolve disease complexity. This includes molecular, biochemical, bioengineering and bioinformatic strategies in disease biology, diagnostics, screening and translational medicine. The session will emphasize the application of state-of-the-art, quantitative, high-throughput and high-resolution approaches to both cellular models and complex tissues. These strategies enable multiparametric computational analyses to reveal the complex interplay of genetics, cell types and drugs to advance precision medicine. Topics include improvements in stem cell-based disease modeling, bioengineering, molecular and cellular assay and bioinformatic approaches. Planned sessions include:
Closing the Gap Between Assay and Patient
Session Chair: Stephane Richard, Ph.D., Oncodesign
Applications of Single-Cell Analysis to Disease Studies
Session Chair: Nichol Miller, Ph.D., Pfizer
Session Chair: Kate Hastie, Ph.D., La Jolla Institute for Immunology
While SLAS2021 has gone digital, that doesn’t mean the opportunity to create a spark with your product or service has fizzled out. The new format will bring new and exciting ways for you to accelerate your branding and outreach.
Read below for up-to-date information on how current and prospective sponsors and exhibitors can navigate the new format.
SLAS2021 Digital Exhibition and Sponsorship Information
A timeline and list of FAQs have been put together to ensure both current and prospective sponsors and exhibitors know what to expect over the next few weeks and months. Please contact Amy Wilkinson, SLAS Director, Global Events, with any questions.
SLAS2021 confirmed exhibitors will have three options available for SLAS2021 Digital:
There is no action needed on your part at this time. The SLAS Professional team will reach out to every confirmed exhibitor to set up a one-on-one appointment to confirm your decision for SLAS2021 Digital. The timeline for the SLAS2021 Digital sales process is as follows:
Not confirmed for SLAS2021 yet, but want to participate in SLAS2021 Digital? The new exhibitor and sponsorship prospectus will launch in late-September. SLAS will begin accepting new contracts at that time.
Hold tight! We’ve got more information coming your way soon!
Questions? Please contact Amy Wilkinson, SLAS Director, Global Events.
FAQs (to hold you over in the meantime):
What will happen to my balance paid on SLAS2021? There are three options, all listed above. Please take look, we’ll do whatever is best for you and your company.
I have an outstanding invoice due in September. Do I need to pay that? What should I do with it? Ignore it! We’ll work together to find the best solution for you and your company at SLAS2021 Digital which will result in new billing.
When will SLAS2021 Digital take place? January 25, 26 and 27, 2021.
What platform is SLAS using to present this event? TBD for now. We are exploring many platforms and working to select the best option to serve the SLAS community.
When will booth and sponsorship options be available for SLAS2021 Digital? By the end of September. See above for details.
What is the cost of registration for SLAS2021 Digital? Glad you asked! This event will be available FREE to SLAS Members (with dues paid through the 2021 calendar year). The barrier for entry is quite low and we hope you’ll invite your customers to join us!
What will the virtual exhibition look like at SLAS2021 Digital? Details are forthcoming, but this event will include a virtual exhibition hall, on-demand video meetings in your booth, digital sponsorship opportunities, the New Product Award, Solutions Spotlight and exhibitor content and education opportunities as well as real-time access to your leads.
Who is my main contact for SLAS2021 Digital Exhibits and Sponsorship opportunities and logistics? That would be Amy Wilkinson, SLAS Director, Global Events. Feel free to contact her with any questions or concerns.
Submit your research for presentation and award consideration at SLAS2021 Digital.
Scientists, engineers, academics, and business leaders from academia, government and industry are invited to submit podium and poster abstracts in a wide range of cutting-edge educational tracks. Contributions from graduate students, post-doctoral associates and junior faculty are highly encouraged.
Emerging companies and organizations: Submit your new product or service for the opportunity to be placed within Innovation AveNEW and to compete for the highly-coveted New Product Award. Innovation AveNEW participants may also compete for the SLAS Ignite Award which includes a $5,000 cash prize.
Podium Abstract Submissions Due:
Monday, September 14, 2020
Innovation Award Submission Deadline:
Monday, September 14, 2020
Tony B. Academic Travel Award Podium Submissions Due:
Monday, September 14, 2020
Tony B. Academic Travel Award Poster Submissions Due:
Monday, October 5, 2020
Podium Abstract Decisions Communicated:
Monday, October 12, 2020
Innovation AveNEW Application Deadline:
Monday, October 12, 2020
Poster Abstract Submissions Due:
Monday, October 19, 2020
(Deadline for inclusion in Student Poster Competition)
Monday, January 11, 2021
(Final Poster Abstract Submission Deadline)
Poster Abstract Decisions Communicated:
Beginning October 28, 2020
(On a monthly basis thereafter through Final Deadline.)
SLAS Ignite Award Opt-In Deadline:
Monday, November 23, 2020
New Product Award Application Deadline:
Monday, January 4, 2021
Learn more about the SLAS Innovation Award, a $10,000 cash prize recognizing the extraordinary work behind one unique and special podium presentation.
The Tony B. Academic Award Program is an exclusive opportunity for presenters to get additional funding for the SLAS International Conference and Exhibition. Students, graduate students, postdoctoral associates and junior faculty are encouraged to apply. Click here for complete details on the Tony B. Academic Award program.
The SLAS Student Poster Award recognizes innovative research by students, graduate students, post-doctoral associates and junior faculty (less than four years in first academic appointment) who are chosen to present a poster during SLAS2021. The Top 3 winners will receive a cash award of $500 each!
The SLAS Ignite Award recognizes the best start-up or emerging company exhibiting within Innovation AveNEW.
Companies selected for Innovation AveNEW, and who opt-in to compete for the SLAS Ignite Award, will be judged by an SLAS panel on a combination of key concepts, including their marketing plan, market presence and potential; funding prospects; plan for growth and the existence of balanced company leadership, among other qualities.
Gain extra recognition for your company’s new product or service by entering the SLAS New Product Award competition. This is the perfect opportunity to showcase your product through invaluable publicity and visibility.
To simplify your submission process, make sure to have all of your materials together prior to submitting your abstract. Screenshots of each step in the abstract process will be viewed by using the 'Guidelines' section of the submission site.
To submit, the following documents are needed:
To view a sample abstract, which adheres to these guidelines, please click here.
Selected speakers must agree to the following:
All presenters must be registered as full conference participants. Limited funds may be available to assist with travel and/or hotel funding. These funds are based on availability and financial need. Contact Meghan Schofield at firstname.lastname@example.org for more information.
All poster presenters must be registered as full conference unless you are registered as an SLAS exhibitor.